相似文献
1
What is in a name? Refined diagnostic criteria for prognostic assessment in myelodysplastic syndrome (MDS).
Leuk Res. 2004 Jun;28(6):543-4. doi: 10.1016/j.leukres.2003.11.008.
2
[Myelodysplastic syndrome].
Gan To Kagaku Ryoho. 2005 Mar;32(3):287-91.
3
Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
Leuk Res. 2004 Jun;28(6):551-7. doi: 10.1016/j.leukres.2003.10.016.
4
Refractory anemia and the myelodysplastic syndromes.
Clin Lab Sci. 2004 Summer;17(3):178-86.
5
Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Leuk Res. 2006 Aug;30(8):971-7. doi: 10.1016/j.leukres.2005.11.015. Epub 2006 Jan 19.
6
Myelodysplastic syndromes clinical practice guidelines in oncology.
J Natl Compr Canc Netw. 2006 Jan;4(1):58-77.
7
A comparative review of classification systems in myelodysplastic syndromes (MDS).
Semin Oncol. 2005 Aug;32(4 Suppl 5):S3-10. doi: 10.1053/j.seminoncol.2005.06.021.
8
[Myelodysplastic syndromes].
Ann Biol Clin (Paris). 1985;43(4):369-79.
9
Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Leuk Res. 2004 Jun;28(6):587-94. doi: 10.1016/j.leukres.2003.11.001.
10
Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
Intern Med J. 2008 Nov;38(11):824-8. doi: 10.1111/j.1445-5994.2007.01582.x. Epub 2008 Feb 15.
Zotero 插件